

Haematologica
HAEMATOL/2019/243121
Version 4

Bone marrow niche dysregulation in myeloproliferative neoplasms

Natalia Curto-Garcia, Claire Harrison, and Donal P. McLornan

Disclosures: CH declares Research funding Novartis Institutional and speaker funding Novartis, Celgene, CTI, Gilead, Shire, Roche, Janssen, AOP pharma Advisory board CTI, Novartis, Roche, AOP pharma, Celgene DM declares JAZZ Pharmaceutical speaker fees, advisory boards and speaker bureau. Novartis and Celgene speaker fees. NCG has no disclosures

Contributions: All authors contributed to the concept of the review, its structure and content. All authors wrote and agreed the final version.